What Is MASH? A Plain-English Guide to Metabolic Liver Disease

What MASH Stands For

MASH stands for Metabolic dysfunction-Associated SteatoHepatitis. You may also hear the terms MAFLD (Metabolic dysfunction-Associated Fatty Liver Disease) and MASLD (Metabolic dysfunction-Associated Steatotic Liver Disease). These terms represent the broader condition and are often used interchangeably by healthcare professionals in Australia.

More Than Just "Fatty Liver"

In plain English, MASH is a combination of a fatty liver, inflammation, and early scarring. It is not just having fat in your liver—it is the specific stage where liver cells are being actively damaged by that fat and inflammation.

Why It Matters

If left undetected and unmanaged, MASH can progress to cirrhosis (severe scarring of the liver) and even liver cancer. One of the biggest challenges with MASH is that most people experience absolutely no symptoms until the disease reaches its late stages. Early detection is critical to preventing irreversible damage.

Who Is at Risk?

MASH is closely linked to metabolic conditions. You are at a higher risk if you have Type 2 Diabetes (T2DM), obesity, a high BMI, or metabolic syndrome. According to the AusDiab study, the prevalence of MAFLD in Australia is estimated to be around 37%, making it a significant public health issue.

How It's Diagnosed

The journey to diagnosing MASH typically follows these steps:

1. Blood Test (FIB-4): A simple blood test used by your GP to calculate your FIB-4 score, which assesses your risk of advanced liver fibrosis.
2. Elastography: If your FIB-4 score indicates a risk, the next step is a non-invasive liver elastography scan to accurately measure liver stiffness and fat levels.
3. Biopsy: In some cases, if further clarification is needed after elastography, a liver biopsy may be required.

Treatment Options

Currently, lifestyle modifications—such as diet changes, weight loss, and exercise—are the primary treatment for MASH. However, the medical landscape is evolving. New pharmacological options, such as resmetirom, have been approved internationally and represent a significant step forward in treating the condition directly.